JMP Securities Reaffirms “Market Outperform” Rating for Evolent Health (NYSE:EVH)

Evolent Health (NYSE:EVH)‘s stock had its “market outperform” rating reissued by analysts at JMP Securities in a report issued on Friday,Benzinga reports. They currently have a $12.00 target price on the technology company’s stock. JMP Securities’ price target indicates a potential upside of 19.23% from the stock’s current price.

Other equities research analysts also recently issued research reports about the stock. BTIG Research cut their target price on shares of Evolent Health from $36.00 to $29.00 and set a “buy” rating for the company in a research report on Tuesday, December 3rd. UBS Group reduced their price objective on Evolent Health from $27.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, January 16th. JPMorgan Chase & Co. dropped their target price on Evolent Health from $15.00 to $13.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Royal Bank of Canada reduced their price target on Evolent Health from $20.00 to $17.00 and set an “outperform” rating for the company in a report on Tuesday, January 14th. Finally, Oppenheimer dropped their price objective on Evolent Health from $28.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday, January 24th. One equities research analyst has rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $17.92.

Evolent Health Price Performance

Shares of EVH opened at $10.07 on Friday. The business’s 50-day moving average is $10.86 and its 200-day moving average is $19.24. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04. The company has a market capitalization of $1.17 billion, a price-to-earnings ratio of -11.06 and a beta of 1.45. Evolent Health has a fifty-two week low of $9.45 and a fifty-two week high of $35.00.

Institutional Trading of Evolent Health

Several large investors have recently modified their holdings of the company. Covestor Ltd lifted its position in Evolent Health by 138.1% during the 3rd quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock worth $40,000 after acquiring an additional 826 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Evolent Health by 5,365.5% in the third quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock worth $45,000 after purchasing an additional 1,556 shares during the period. Summit Creek Advisors LLC lifted its position in shares of Evolent Health by 0.8% during the 4th quarter. Summit Creek Advisors LLC now owns 202,114 shares of the technology company’s stock worth $2,274,000 after purchasing an additional 1,636 shares during the last quarter. Creative Planning boosted its stake in Evolent Health by 12.2% during the 2nd quarter. Creative Planning now owns 18,091 shares of the technology company’s stock valued at $346,000 after purchasing an additional 1,973 shares during the period. Finally, Pilgrim Partners Asia Pte Ltd acquired a new stake in Evolent Health in the 4th quarter valued at approximately $26,000.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.